USA flag logo/image

An Official Website of the United States Government

New anti-complement therapy to reduce reperfusion injury: Phase II

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75698
Program Year/Program:
2008 / STTR
Agency Tracking Number:
HL079855
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ENDOPROTECH, INC.
1044 E CHESTNUT ST LOUISVILLE, KY 40204-1019
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: New anti-complement therapy to reduce reperfusion injury: Phase II
Agency: HHS
Contract: 2R42HL079855-02A1
Award Amount: $963,666.00
 

Abstract:

DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to develop a local anti-complement therapy for donor organ e x vivo application that will reduce complement-induced injury to the vascular endothelium. An unavoidable consequence of transplantation (allografts or autografts) is ischemia/reperfusion (IR) injury. Studies have shown that IR-induced complement activatio n leads to the formation of several key inflammatory mediators that alter vascular homeostasis and stimulate leukocyte activation and chemotaxis. After decades of neglect, complement has been rediscovered as a potent mediator of inflammation and rejection in organ transplants. In Phase I of this proposal, we successfully provided proof-of-concept that our novel therapy reduced complement deposition in vitro after activation of the classical pathway. Our therapy is based on a platform technology that allows the rapid display of protective exogenous proteins on the surface of cells during organ harvest. The goal in Phase II is to prepare the technology for clinical use. This will be accomplished by developing safe and stable lyophilized components, which upon reconstitution, are perfused into organs ex vivo to effectively reduce locally complement mediated injury in vivo. The technical objectives are: 1) Reduce cost of therapeutic formulations by using the most economical components without compromising anti-co mplement efficacy. 2) Determine potential toxicity of therapy and demonstrate its efficacy in a kidney rat model of IR. 3) Develop stable lyophilized therapeutic components for storage and demonstrate in vitro that reconstituted components are just as effe ctive as freshly prepared components. 4) Demonstrate in kidney rat models of IR and transplantation that lyophilized products are effective in reducing antigen-independent and antigent-dependent IR injury. If successful these studies will demonstrate the p otential clinical value of our therapy in enhancing natural anti-complement defenses in allografts. Our therapy will be applied during routine flushes of donor organs and will achieve therapeutic levels of drug locally without systemic adverse effects. App lication of our therapy may extend the donor pool by allowing organ harvest from non-beating heart donors. Our approach is a faster alternative to gene therapy, in that proteins can be displayed on the cell membranes in less than 1 hour. The economic impli cations for this novel therapeutic approach in transplantation are vast, not only in terms of the potential benefits to patients but also in reducing health care costs associated with re-operations and complications arising from failed procedures. P ublic Health Relevance: The goal of this project is to develop a new targeted therapy that prevents damage to transplanted organs. An unavoidable inherent problem of transplantation is that blood flow during organ harvest must be cutoff and later reestabli shed during implantation. This process causes the activation of the immune component called the complement system, which causes unintended tissue injury that ultimately leads to organ malfunction and failure. Anti-complement agents that are administered sy stemically have been developed but their use leaves transplant recipients vulnerable to viral and bacterial infections. EndoProtech, Inc. is proposing to develop a novel safer anti-complement therapeutic agent that binds to cells of transplanted organs and eliminates systemic circulation of the agent. The therapy is applied during harvest while organs are outside the body before implantation. The objective is to protect tissues from complement-related injury with minimal side effects.

Principal Investigator:

Business Contact:


claudio@endoprotech.com
Small Business Information at Submission:

ENDOPROTECH, INC.
ENDOPROTECH, INC. 1060 E CHESTNUT ST LOUISVILLE, KY 40204

EIN/Tax ID: 270087238
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No